Retifanlimab

Zynyz

Concentrato per soluzione per infusioneItalyAuthorised

In other countries

The same active substances on other registers, the same brand first.

ZynyzCanada · 25 MG / ML · Solution · Incyte CorporationSame brand
Zynyz 500 MG Concentrado Para Solucion Para PerfusionSpain · 500 mg · concentrado para solución para perfusión · Incyte Biosciences Distribution B.V.Same brand
ZynyzEuropean Union · Incyte Biosciences Distribution B.V.Same brand
ZynyzEuropean Union · Incyte Biosciences Distribution B.V.Same brand
ZynyzCroatiaSame brand
ZYNYZ 500 mg concentraat voor oplossing voor infusieNetherlands · Concentraat voor oplossing voor infusie · Incyte Biosciences Distribution B.V.Same brand
ZynyzUnited States · 500MG/20ML · injectable · Incyte CorpSame brand

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Retifanlimab

Zynyz

Concentrato per soluzione per infusioneItalyAuthorised

Product informationAsk Osler about it

In other countries

The same active substances on other registers, the same brand first.

Two medicines in one question?

Name two or more medicines and Osler runs an interaction check. A severe interaction is stated at the very top of the answer.

Discover Osler

Packs

Pack	Code	Status
500 mg - Concentrato per soluzione per infusione - Uso endovenoso - Flaconcino (vetro) 20 ml (25 mg/ml) - 1 flaconcino	051172017	Autorizzata

Documents

The official texts, at the regulator.

Sources and licences

Compiled by Prognia from the public register below; the register’s text is the official one.

Agenzia Italiana del Farmaco (AIFA), Italy

Agenzia Italiana del Farmaco (AIFA); https://drive.aifa.gov.it/farmaci/confezioni_fornitura.csv; HTTP Last-Modified Mon, 12 Oct 2026 23:02:44 GMT; acquired 2026-10-13T17:21:16.224007+00:00; native fields retained, source identifier and role projections are adaptations.

Licence: CC BY 4.0; AIFA published open-data catalog · Added 13 Oct 2026

Report an error or request removalCorrections from the holder or the register are welcome.

Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.

At a glance

Active substance: Retifanlimab
Dosage form: Concentrato per soluzione per infusione
Register: Italy (AIFA)
Status: Authorised
Status in the register: Autorizzata
Registration: AIC 051172
Marketing authorisation holder: Incyte Biosciences Distribution B.V.
ATC code: L01FF10
Group: Antineoplastic and immunomodulating agents
Procedure: Procedura Centralizzata
Supply: Medicinali soggetti a prescrizione medica limitativa, utilizzabili esclusivamente in ambiente ospedaliero o in una struttura ad esso assimilabile